A meta-analysis of 41 studies, published Oct. 28, 2026, in JAMA Dermatology, found that response rates to targeted and immune-based drugs for cutaneous T-cell lymphoma ranged widely, led by brentuximab vedotin at 69%.
An analysis of 580 people with lymphoma treated with the CAR-T therapy axi-cel, published Oct. 23, 2026, in Nature Medicine, found that products with more naive-like T cells were linked to longer progression-free survival (hazard ratio 0.46).